Please assess the completion status of the following clinical trial:

Trial Title: Sevoflurane Associated With Oral Midazolam and Ketamine for Dental Sedation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children ASA I or II;~* Need for restorative procedure on at least one deciduous tooth below;~* Airway patent and effective nasal breathing;~* Behavior not collaborator in previous dental treatment.~Exclusion Criteria:~* Previous experience of dental treatment under sedation;~* Have completed seven years during the data collection.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- Midazolam and Ketamine (Type: ACTIVE_COMPARATOR): In this arm, the children received, orally, the combination of midazolam and ketamine. Midazolam, at a dose of 0.5 mg/kg (maximum dose 20 mg) and ketamine, at a dose of 3 mg/kg (maximum dose 50 mg). This combination of drugs were administered fifteen minutes before the start of treatment sessions.
- Midazolam, Ketamine and Sevoflurane (Type: EXPERIMENTAL): In this arm, the children received, orally, the combination of midazolam and ketamine. Midazolam, at a dose of 0.5 mg/kg (maximum dose 20 mg) and ketamine, at a dose of 3 mg/kg (maximum dose 50 mg). After fifteen minutes of this drug administration, the investigators start to provide sevoflurane, through a nasal hood, in an initial concentration of 0.1%, with 0.1% increment every 30 seconds, until a final expired concentration between 0.3 and 0.4%.

Based on this trial design, predict the completion outcome and termination type (if applicable).